CHEK2 and lung cancer: Taking the advantage of enrolling large number of controls, we found that despite the fact that P/LP variants of ATM, CHEK2, PALB2, and TP53 were enriched in lung cancer patients, only TP53 exhibited statistical significance with an OR of 29.281 (95% CI, 1.523–1705.506, p = 0.012).